Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by McAllister, S. M.
Right arrow Articles by Brown, M. R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McAllister, S. M.
Right arrow Articles by Brown, M. R. W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 43, 203-210
© 1999 The British Society for Antimicrobial Chemotherapy

Antimicrobial properties of liposomal polymyxin B

S. M. McAllistera, H. O. Alparb,* and M. R. W. Brownb

a SmithKline Beecham Pharmaceuticals, Drug Delivery group, Harlow CM17 5AW, Essex b Pharmaceutical Sciences Institute, Aston University, Birmingham B4 7ET, UK

The pulmonary residence time of polymyxin B has been shown to be substantially increased when administered as a liposomal formulation. The use of this system to improve the treatment of cystic fibrosis lung infections requires that the antimicrobial activity of polymyxin B is unaffected by the encapsulation process. To verify that activity against the target organism, Pseudomonas aeruginosa, was retained, the bactericidal activity and MICs of both free and encapsulated polymyxin B were determined. The roles of liposomal surface characteristics in determining interactions with bacterial cell surfaces were also investigated. Encapsulation of polymyxin B was reduced when the positively charged amphiphile, stearylamine (SA) was present, with entrapment efficiencies being lower than with neutral (egg phosphatidylcholine, EPC) or negatively charged (egg phosphatidylcholine:dicetylphosphate, EPC:DCP) formulations (EPC, 45.41%± 0.51%; EPC:DCP 9:1, 50.81% ± 0.79%; EPC:SA 9:1, 31.92% ± 2.08%, n x 3). The bactericidal activities were compared, and it was found that polymyxin B retained antimicrobial activity after encapsulation. At a polymyxin B concentration of 0.3 mg/L, both positively and negatively charged liposomal polymyxin B formulations, and free drug, killed all cells after 1 h. In contrast, neutral liposome formulations did not significantly decrease the surviving cell fraction. At 0.1 mg/L, fewer cells were killed, and all liposomal formulations produced a reduction in cell numbers, which was not significantly different from free drug. It was found that the MICs of liposomal formulations were attributable to the free drug concentration achieved through release of entrapped polymyxin B. Enhanced activity was seen only with positively charged EPC:SA liposomes and those containing distearoylphosphatidylcholine (DSPC) as the bulk phospholipid. This is likely to be the result of favourable electrostatic interactions and increased liposome:cell ratios respectively. In summary, liposome encapsulation of polymyxin B was not detrimental to antimicrobial activity, and liposome surface properties and release characteristics were important in determining interactions with bacterial cells.

* Corresponding author. Fax:+44-121-359-0733; E-mail: alparho{at}aston.ac.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.